☰

Bramble Bio

One data spine for a multi-site cell therapy CDMO

Industry
Cell and Gene Therapy CDMO
Headquarters
Warsaw, Poland
Public information as of
February 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Bramble Bio's published strategy and is not endorsed by, or produced in cooperation with, Bramble Bio. Company website

Strategic priorities

Bramble Bio is the cell and gene therapy CDMO (Contract Development and Manufacturing Organisation) brand of the FamiCord Group, headquartered in Warsaw with two GMP-certified ATMP (Advanced Therapy Medicinal Product) production facilities and a network of 15 laboratories across Europe, the Middle East and Asia. The company rebranded from FamiCord Cell and Gene Manufacturing to Bramble Bio in January 2025, and the parent FamiCord AG rebrand from Vita 34 AG was completed on 6 February 2025.

The CDMO market for Advanced Therapy Medicinal Products is forecast to grow from USD 8.7 billion in 2024 to over USD 76 billion by 2030. Bramble's stated 5-7 year goals align with that growth: 100% digital lab readiness by 2030, end-to-end visibility of the cryo-supply chain, full integration of recent acquisitions (nOvum in September 2025, majority stakes in Czech and Slovak banks in May 2025) into one operational framework by 2026, and a Net-Zero roadmap.

Revenue guidance for the FamiCord Group reached EUR 85-95 million in 2025 with an EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortisation) margin around 11 percent, and a forecast of EUR 12 million EBITDA in 2026. The new-build cost pressure on cryopreservation - operating at approximately -196 degrees Celsius across more than 1,000,000 stored samples - and the ATMP market's own scaling curve are what the digital work is meant to absorb.

The shared underlying capability across all four pillars is the same: process, sample, lot and shipment data that can be read across sites, across regulatory scopes and across the technologies acquired through M&A (mergers and acquisitions), without being rebuilt every time a new line, lab or country comes online.

Challenges we see

  • Digital Integration

    Unifying operational data across acquired laboratories

    The FamiCord Group has acquired nOvum (September 2025), majority stakes in Czech and Slovak stem cell banks (May 2025), and rolled out placenta banking across Switzerland, Poland, Romania, the GCC and Italy in 2024. The 15 laboratories carry separate IT systems and operational protocols.

    Where each acquired site ships data in its own structure, the work of building a unified view is repeated at every new report, model or audit. Carrying an agreed ontology for sample, lot, instrument and assay moves that work upstream into the data layer.

  • Operations Manufacturing

    Predicting batch outcomes before physical manufacturing

    Starting materials for ATMPs are derived from living human cells, which are inherently variable. Bramble Bio runs 16 production suites in Warsaw and operates an analytical centre of excellence in Cantanhede, Portugal, with 723+ patients dosed and 1,000,000+ samples stored across the network.

    When each batch carries the variability of its donor, the relevant question becomes what signals correlate with a good outcome, and where they can be observed in the data a process already produces. Capturing those signals at process time lets deviations be modelled against the running batch.

  • Operations Manufacturing

    Capturing operator expertise as digital procedures

    Many of Bramble Bio's processes remain manual or semi-manual and rely on the practical, non-written expertise of operators, particularly across the 16 production suites in Warsaw.

    Where the steps that matter live in an operator's head, scaling the operation means training every new person the same way. Writing the procedure once in a form that records both the steps and the reasoning behind each decision makes that institutional knowledge reachable for the next shift.

  • Operations Operations

    Tracking cell shipments at cryogenic temperatures end-to-end

    Autologous cell therapies are cryopreserved at approximately -196 degrees Celsius and transported back to hospitals for administration. Bramble Bio's services reach 50+ countries and the volume of patients dosed is rising on a market forecast to grow at roughly 44 percent CAGR (Compound Annual Growth Rate) through 2030.

    Where the chain of custody relies on handoff logs that are reconciled after the fact, a deviation is found by reconstruction rather than observation. Each handoff producing its own timestamped, temperature-attested record shortens that window from days to minutes.

  • Compliance Regulatory

    Producing compliance evidence across EMA and FDA scopes

    Bramble Bio operates in the ATMP space with international expansion, including dual GMP-certified facilities, and faces EMA (European Medicines Agency) and FDA (US Food and Drug Administration) divergence including the Qualified Person role. The parent group is also committed to a 2030 Net-Zero Roadmap requiring site-level energy reporting.

    When the same change has to be evidenced against two regulatory frameworks and a sustainability programme at once, the bottleneck tends to be the documentation layer. Producing each set of evidence from the same source records, with the framework-specific formatting added at the end, makes the cross-jurisdiction review a query rather than a rebuild.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Unifying operational data across the 15-site network

    Bramble Bio operates 15 laboratories carrying different IT systems and equipment vintages, following the FamiCord Group's acquisition trail including nOvum in September 2025 and the Czech and Slovak banks in May 2025.

    An ontology-based Industrial Data Platform defines sample, lot, instrument and assay as shared entities, so data from each acquired site loads against one model and a corporate analytics layer can query across all sites.

    • Bramble Bio, About us
    • FamiCord AG Annual Report 2024

  2. Modular changeovers across the 16 Warsaw production suites

    The Warsaw facility runs 16 separate production suites with fragmented automation, and Bramble Bio is repurposing infrastructure originally configured for the now-discontinued CAR-T (Chimeric Antigen Receptor T-cell) segment for new CDMO clients.

    Standardising process modules with MTP (Module Type Package, a vendor-neutral standard for plug-in automation modules described in NAMUR VDI/VDE 2658) and OPC UA (Open Platform Communications Unified Architecture, a machine-to-machine communication protocol) lets a new client recipe arrive as a set of compatible modules rather than a from-scratch integration.

    • Bramble Bio, About us
    • Bramble Bio Cell Therapy Insights, June 2025

  3. Codifying tacit knowledge into digital procedures

    Technology transfer at Bramble Bio is described as a puzzle, with information routinely lost or misunderstood between transferring and receiving teams. Many production steps live as operator expertise rather than as written procedures.

    Digital work instructions with embedded media, decision criteria and an assisted-reality layer for new operators let the procedure be the same artefact the experienced operator would use, and shorten the path from one team to the next.

    • Bramble Bio Cell Therapy Insights, June 2025
    • HubXchange, Industry News

  4. Real-time tracking of cryogenic shipments across 50+ countries

    Autologous cell therapies travel at approximately -196 degrees Celsius to and from hospitals across 50+ countries. A temperature deviation or a missed handoff is discovered only after the cells arrive.

    A tracking and alerting layer on each cryogenic shipment, with each handoff producing its own timestamped record, lets logistics teams see a deviation at the moment it occurs and intervene before the therapeutic is at risk.

    • FamiCord, Our Services
    • Bramble Bio Cell Therapy Insights, June 2025

  5. Energy and emissions visibility for cryopreservation facilities

    Cryopreservation facilities are energy-intensive and FamiCord AG has committed to a 2030 Net-Zero Roadmap covering the network of 15+ laboratories and major storage centres.

    Connecting cryogenic storage units to a common monitoring layer and running consumption forecasts against loading and ambient conditions lets the network manage energy and report progress during the year rather than report it afterwards.

    • FamiCord AG Investor Relations, Sustainability Programme
    • FamiCord AG Annual Report 2024

What we'd propose

  • Enterprise AI

    An ontology-based data platform across the Bramble Bio network

    We define the shared entities - sample, lot, instrument, assay, shipment - once, then load the data from each of the 15 laboratories and the CDMO manufacturing systems against that single model so the group sees one network rather than 15 sites.

    • Shared biological-data ontology

      One agreed set of terms

      Define sample, lot, instrument, assay and shipment as explicit entities with agreed relationships, so a query written once returns comparable answers across every acquired site instead of one dialect per site.

    • Ingestion from legacy and current systems

      Loading the historical estate

      Build pipelines into the labs and CDMO systems inherited through the FamiCord acquisitions (including nOvum and the Czech and Slovak banks), with schema validation at the boundary so records that do not match fail loudly rather than silently.

    • Corporate analytics and retrieval

      Questions answered without IT tickets

      Expose the model through dashboards and a retrieval layer so executive, quality and operations teams can interrogate the combined data set without commissioning a new extract for each question.

    • Integration work is done once against a shared model instead of once per acquired site.
    • The 1,000,000+ stored samples become queryable across the network rather than trapped in their site of origin.
    • Future acquisitions attach to the model rather than triggering another migration project.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Modular automation standards for the 16 Warsaw production suites

    An MTP and OPC UA standard for the 16 Warsaw production suites that lets a new client recipe arrive as a set of compatible modules, so changeovers for new CDMO clients stop being integration projects.

    • MTP module library

      Standards-compliant module wrappers

      Wrap each suite's process modules to NAMUR VDI/VDE 2658 so they describe themselves in a vendor-neutral way and a new client recipe picks up the existing modules instead of requesting a fresh programming cycle.

    • OPC UA connectivity layer

      Universal equipment data path

      Bridge bioreactors, incubators and analytical instruments through OPC UA so a single data path reaches the Process Orchestration Layer from equipment of different vintages and vendors.

    • Process orchestration across the 16 suites

      One control plane for the site

      Run a Process Orchestration Layer that manages recipe execution, batch tracking and equipment allocation across all 16 Warsaw suites, so the site operates as one flexible plant rather than 16 parallel ones.

    • A new CDMO client recipe becomes a configuration rather than a from-scratch integration.
    • The infrastructure originally built for the discontinued CAR-T segment is reusable for new therapies.
    • Vendor lock-in is replaced with a published standard the procurement team can specify against.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Digital procedures and assisted-reality operator guidance

    Digital work instructions, AR-assisted guidance for new operators and a searchable procedure repository, so the expertise that currently lives in operators' heads becomes a digital artefact the next team can use.

    • Digital SOPs with embedded media

      Step-by-step procedures that show their work

      Replace static paper procedures with step-by-step digital work instructions that include embedded video, decision criteria and parameter validation, so the procedure carries both the steps and the reasoning behind each decision.

    • AR-assisted operator guidance

      Expert reach into a new suite

      Equip operators with assisted-reality glasses so an experienced operator in one site can walk a new operator in another site through a critical cell-manipulation step, with the camera view and the spoken guidance captured in the procedure.

    • Procedure and deviation repository

      Searchable expertise

      Build a structured repository of procedures, deviation histories and troubleshooting resolutions, so the experience of one suite is queryable across the network.

    • New operators and new sites start with the procedure the experienced team already uses.
    • Technology transfer between Warsaw and Cantanhede becomes a documentation transfer rather than a people transfer.
    • Deviation histories become a learning asset rather than a paper archive.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Continuous visibility for the cryogenic cell shipment chain

    A tracking and alerting layer on each cryogenic shipment, with each handoff producing a timestamped, temperature-attested record, so the logistics team sees a deviation at the moment it occurs.

    • Cellular-connected cryogenic sensors

      Sensors that travel with the shipment

      Fit each cryogenic shipment with a cellular-connected sensor that streams temperature and GPS location to a central platform throughout transit, with redundant transmission so a single network outage does not break the chain.

    • Central monitoring and alerting layer

      Every shipment on one screen

      Build a centralised platform showing the live status of every in-transit shipment, with predictive ETA, temperature history and automatic alerts when a reading crosses an agreed threshold.

    • Chain-of-custody automation

      Digital handoff evidence

      Capture each handoff with a QR-verified timestamp, temperature confirmation and digital signature, so the regulatory chain of custody is generated by the process rather than reconstructed for the audit.

    • A temperature deviation is visible to the logistics team within minutes, not after delivery.
    • Every handoff is an evidence record, so chain of custody is built in transit rather than rebuilt afterwards.
    • The 50+ country footprint runs on one monitoring layer rather than on per-country reconciliation.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Energy and emissions monitoring for cryogenic storage

    We connect the cryogenic storage units to a common monitoring platform, forecast consumption against loading and ambient conditions, and generate the per-site evidence the 2030 Net-Zero Roadmap requires.

    • Cryotank energy analytics

      Live power data per unit

      Connect each cryogenic storage unit to a central monitoring layer so power consumption is visible at the unit, site and network level, with the data feeding the group's 2030 Sustainability Programme.

    • Predictive load management

      Forecast the cooling demand

      Build consumption forecasts from sample loading, ambient temperature and historical cycling patterns, so compressor cycling and peak demand can be planned rather than reacted to.

    • Automated ESG evidence

      Reports generated as the data lands

      Generate the per-site energy and carbon reports the 2030 Net-Zero Roadmap requires directly from the monitoring layer, so the evidence is produced by the network rather than assembled for the audit.

    • Energy reporting is produced by the network rather than compiled for the audit.
    • Compressor cycling is planned against a forecast rather than driven by alarms.
    • Progress against the 2030 commitment is visible during the year, not just at reporting time.

    We've done this before

    See how we do Enterprise AI

Where QB Systems fits

Alongside our services we build QB Systems, hardware and software for bioprocess control. QB Systems is a product brand of A4BEE Sp. z o.o.

Applications
Bioreactors

Software-defined control for a bioreactor — a new QB vessel, an upgrade to one you have, or a retrofit of the existing PLC.

Automated sampling

Automated sampling from 4–18 sources, aseptic-capable and up to 72 hours unattended. Works with any vendor's bioreactor.

Filtration (TFF)

Benchtop tangential flow filtration for concentration, diafiltration and buffer exchange.

Deployment
Retrofit

Existing equipment keeps running; QB takes over the PLC, or reads from it without touching control.

Scale
Benchtop (1–8 L)

Glass vessels with the complete hardware and software stack. This is the core range for development work.

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Bramble Bio's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Integration 35 → 85
15 laboratories carry separate IT systems following the FamiCord Group's acquisition trail including nOvum and the Czech and Slovak banks. The shared ontology work is ahead of the network rather than behind it.
Process Automation 40 → 80
The 16 Warsaw production suites carry fragmented automation across different vintages, and many cell-manipulation steps remain manual. MTP standardisation and digital procedures are the two named intervention paths.
Supply Chain Visibility 45 → 90
The cryogenic cell shipment chain across 50+ countries relies on handoff logs reconciled after the fact. Cellular-connected sensors and a central monitoring layer are the path from reconciliation to observation.
Knowledge Management 30 → 75
Many of the procedures that matter live in operator expertise rather than in written form, and Bramble Bio describes technology transfer itself as a puzzle where information is lost or misunderstood.
IT/OT Convergence 35 → 80
Many of the 15 laboratories operate on legacy equipment not connected to a modern data lake, and the equipment vintages inherited through M&A vary. The shared data platform and OPC UA layer are the convergence path.
Sustainability Analytics 25 → 70
Cryopreservation is energy-intensive and the parent group has committed to a 2030 Net-Zero Roadmap. The monitoring layer for that commitment is being built rather than already in place.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of February 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Bramble Bio, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].